Heather M Moore
6PUBLICATIONS
50CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jan 13, 2025
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer.Jackson Liang, Xiaosai Yao, Patrick Aouad
|Mar 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor
|Feb 22, 2024
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape.Nayan Chaudhary, Alejandro M Chibly, Ann Collier
|Nov 03, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner
|Jun 01, 2023
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.Sarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo
|Sep 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao
Pageof 1
Frequent Collaborators
3 joint publications
Ciara Metcalfe
3 joint publications
Aditya Bardia
3 joint publications
Ching-Wei Chang
2 joint publications
Jose Alejandro Perez Fidalgo
2 joint publications
Mary R Gates
2 joint publications
Jennifer Giltnane
2 joint publications
Jill Fredrickson
2 joint publications
Rafael Villanueva-Vázquez
2 joint publications
Marc Hafner
2 joint publications
Meritxell Bellet
